10x Genomics, Inc. Class A Common Stock (TXG) Valuation
Historical valuation analysis based on 500 data points (2024-09-27 to 2026-09-25)
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integr...
10x Genomics, Inc. Class A Common Stock (TXG) currently trades at a P/S ratio of 17.21 (range: 1.40–17.21, 100th percentile — expensive relative to its history).
10x Genomics, Inc. Class A Common Stock trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/S Ratio | 17.21 | 1.40 | 3.02 | 17.21 | 100th | expensive relative to its history |
| FCF Yield | 1.11% | 0.96% | 3.30% | 5.74% | 2th | expensive relative to its history |
10x Genomics, Inc. Class A Common Stock (TXG) Valuation & P/E History
10x Genomics, Inc. Class A Common Stock (TXG) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry currently trading at $85.50 with a market capitalization of $11.1 billion. This page provides historical valuation analysis for TXG based on 500 data points covering 2024-09-27 to 2026-09-25.. The P/S ratio of 17.21 compares to a median of 3.02.
TXG Valuation Metrics & Historical Range
The valuation table above shows 10x Genomics, Inc. Class A Common Stock's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether TXG is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests TXG is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for 10x Genomics, Inc. Class A Common Stock.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is TXG Overvalued or Undervalued?
10x Genomics, Inc. Class A Common Stock trades well above its own historical valuation range across most metrics. The overall valuation percentile of 100 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive TXG is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full TXG analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.TXG trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.